Abstract
The Canadian Inflammatory Myopathy Study (CIMS) is a multicenter prospective cohort recruiting in 8 centers across Canada. One of the aims of CIMS is to conduct and participate in clinical trials in autoimmune inflammatory myopathies (AIM). Conducting clinical trials in rare diseases such as AIM presents challenges. During this symposium, experts in the field presented different solutions to successfully conduct clinical trials in AIM, including the importance of collaboration and careful trial design, as well as training and mentoring of young investigators.
Publisher
The Journal of Rheumatology
Subject
Immunology,Immunology and Allergy,Rheumatology
Reference18 articles.
1. Health-related quality of life (HRQOL) in idiopathic inflammatory myopathy: A systematic review;Leclair;PLoS One,2016
2. A comparison of health-related quality of life (HRQOL) across four systemic autoimmune rheumatic diseases (SARDS);Greenfield;PLoS One,2017
3. Nailfold videocapillaroscopy in idiopathic inflammatory myopathies;Bangert;J Rheumatol,2018
4. 18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications;Maliha;Nucl Med Commun,2019
5. Extensive interstitial lung disease in inflammatory myopathy is a strong predictor of mortality. European Respiratory Society International Congress, 2017; Milan, Italy;Assayag;Eur Respir J,2017